Boston Cambridge Biotech Networks

BCBN Feed: Boston Business Journal: BiotechTV’s new MassBio studio helps bring Kendall Square to the world https://lnkd.in/gtv4AdaM The following is an excerpt from an article in the Boston Business Journal first published on October 28, 2024: Brad Loncar is a longtime biotech investor who’s on a mission to take the types of conversations that regularly happen in coffee shops around Cambridge’s Kendall Square and “broadcast it to... ... [...]

BCBN Feed: The making of the gut https://lnkd.in/g49RCftM Studies connect genetics, physics in embryonic development  ... [...]

BCBN Feed: MIT Schwarzman College of Computing launches postdoctoral program to advance AI across disciplines https://lnkd.in/gk6D5DZR The new Tayebati Postdoctoral Fellowship Program will support leading postdocs to bring cutting-edge AI to bear on research in scientific discovery or music. ... [...]

BCBN Feed: Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET https://lnkd.in/gxSGw9k4 HOLLISTON, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2024 before the market opens on November 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  ... [...]

BCBN Feed: Zurzuvae won’t be developed for major depression, Sage says https://lnkd.in/gX-CP56N It’s official: Sage and Biogen will not attempt to get their postpartum depression pill Zurzuvae approved in the broader population of people with major depressive disorder. Sage, which has recently gone through waves of layoffs ... ... [...]

BCBN Feed: Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases https://lnkd.in/g597HDx3 CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for priority targets in Alzheimer’s, rare neurological, and immunological diseases. ... [...]

BCBN Feed: Sage to sunset first postpartum depression drug, focus on Zurzuvae https://lnkd.in/gYbn4kuk Following a series of disappointing trial results in 2024, Sage Therapeutics Inc. is taking new steps to focus its resources on its recently approved treatment for postpartum depression. ... [...]

BCBN Feed: EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering https://lnkd.in/g_bDfwyU WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the pricing of an underwritten public offering of 12,727,273 shares of its common stock at... ... [...]

BCBN Feed: LabCentral and Astellas Announce Diamond Ticket Winner Quantum Sky https://lnkd.in/gV-n53sP $500,000 credit for private biomanufacturing lab space at LabCentral 238 supports growth trajectory for AI modeling biotech startup CAMBRIDGE, Mass., Oct. 29, 2024 /PRNewswire/ -- LabCentral, the Massachusetts-based network of coworking labs designed to accelerate high-potential biotech... ... [...]

BCBN Feed: NIST Renews Five-Year Contract With MITRE to Operate the National Cybersecurity FFRDC https://lnkd.in/gSCqEy9Q MCLEAN, Va. & BEDFORD, Mass.--(BUSINESS WIRE)--MITRE announced that the National Institute of Standards and Technology (NIST) renewed its contract to operate the National Cybersecurity Federally Funded Research and Development Center (NCF). This five-year contract, extending through 2029, will foster continued collaboration and innovation to enhance national and economic security through... ... [...]